Merck Launches New BioReliance Facility in Germany

Merck has unveiled its newest BioReliance® facility in Darmstadt, Germany, marking a significant expansion of its biologics testing capabilities in Europe. The state-of-the-art site is designed to offer comprehensive biologics testing, Good Manufacturing Practice (GMP) release testing, and stability studies tailored for the European market.

The facility is strategically positioned to support the development and commercialization of biologic products within the region. It provides specialized laboratory services essential for regulatory approval and quality control, ensuring that biologic products meet the necessary safety and efficacy standards before entering the market.

By establishing this site in Darmstadt, Merck aims to offer local access to advanced testing protocols, simplifying the commercialization process for pharmaceutical and biotechnology companies. The new facility underscores Merck's commitment to enhancing its infrastructure to meet the growing demands of the biologic therapies sector.